Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair
I'm PortAI, I can summarize articles.
Humacyte Inc. reported findings from a five-year analysis on extremity arterial injury repair costs. The average hospital charge was $316,600 per patient, with preventable complications like amputation and infection raising costs significantly. The study highlighted that Humacyte’s Symvess, an acellular tissue engineered vessel, showed low infection rates and high limb salvage rates. These results were shared prior to Symvess's FDA approval and commercialization.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments